Nutriband Inc. — Form 10-K Summary
Reporting period: Fiscal year ended January 31, 2024. The filing was signed April 30, 2024. This is an annual report, not a report for calendar-year Q4.
Business context
Nutriband develops transdermal pharmaceutical products, led by AVERSA abuse-deterrent patches. Its lead candidate, AVERSA Fentanyl, is not approved for sale. Current revenues come principally from Pocono Pharmaceuticals’ contract manufacturing and Active Intelligence operations, with a smaller contribution from 4P Therapeutics’ contract research and development services. The company reports that it has generated no product revenue from its development pipeline.
Financial results and liquidity
| Metric | FY ended Jan. 31, 2024 | FY ended Jan. 31, 2023 |
|---|---|---|
| Revenue | $2.085 million | $2.080 million |
| Cost of revenue | $1.223 million | $1.329 million |
| Gross profit / margin | $862,105 / 41.3% | $750,409 / approximately 36.1% |
| Research and development | $1.960 million | $982,227 |
| Selling, general and administrative | $3.774 million | $3.916 million |
| Operating loss | $4.872 million | $4.475 million |
| Net loss / loss per share | $5.485 million / $0.69 | $4.483 million / $0.53 |
| Cash used in operations | $3.528 million | $2.987 million |
| Cash and cash equivalents at year-end | $492,942 | $1.985 million |
| Working capital at year-end | $22,770 | $1.945 million |
Revenue was nearly flat year over year. Manufacturing revenue was $1.920 million, while contract R&D revenue was $165,034. Gross profit improved as cost of revenue declined, but higher R&D spending and a $554,423 loss on extinguishment of debt contributed to a larger net loss. The company recorded no goodwill impairment in FY2024, compared with $327,326 in FY2023.
At January 31, 2024, total liabilities were $1.079 million, including $207,009 of notes payable (current and long-term) and $34,276 of current operating lease liability. The related-party credit-line balance was zero after conversion to equity. Working capital was narrow, and operating cash use exceeded cash available at year-end. Investing activities used $51,761; financing activities provided $2.087 million, including $2.0 million drawn on the related-party credit line.
Material developments, outlook and risks
- AVERSA Fentanyl: In January 2024, Nutriband entered a commercial development and clinical supply agreement with Kindeva, replacing the earlier feasibility agreement. The company says the remaining commercial process development and clinical supply work is estimated to cost approximately $8.1 million, with FDA submission expected in 12–18 months. Elsewhere, management estimates approximately $13 million for the broader AVERSA Fentanyl R&D program and cautions that the total could be higher.
- Regulatory and commercial uncertainty: The planned route is a 505(b)(2) NDA, with preclinical testing and a Phase 1 human abuse-potential study described as central to the program. FDA acceptance of the pathway, data, labeling, and any expedited review is not assured. No product is approved, and clinical, regulatory, manufacturing, financing, market acceptance, reimbursement, and competition risks remain significant.
- Financing after year-end: On April 19, 2024, the company completed an $8.4 million private equity financing: 2.1 million units at $4 each, with each unit including one common share and warrants for two additional shares at $6.43, expiring in 2029. The financing occurred after the fiscal year-end and adds potential dilution. The company also reported $300,000 in credit-line proceeds received in February and April 2024.
- Going concern: Management says the April financing and its forecasts alleviate substantial doubt about the company’s ability to continue as a going concern for the look-forward period. This assessment depends on projected funds and operations; the company has a history of operating losses and negative operating cash flow.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were ineffective at January 31, 2024, citing material weaknesses including inadequate review, lack of segregation of duties, limited internal audit capacity, and insufficient monitoring of complex transactions. The independent auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- Legal contingency: Joseph Gunnar and Lucosky Brookman are suing over a terminated engagement letter, seeking more than $500,000 plus punitive damages and legal fees. Nutriband denies the claims and asserts counterclaims seeking $1 million for each of two claims and declaratory relief. The matter was in discovery; the filing does not state a probable loss estimate.
- Other items: The company fully reserved a $118,675 receivable related to Sorrento Therapeutics’ bankruptcy. It received $106,528 through a factoring arrangement but may have to repay amounts if the claim is not paid as agreed. Management also cites low trading volume, possible future dilution, dependence on key personnel and third parties, and a prior SEC cease-and-desist settlement related to earlier disclosure violations.
The filing does not provide quantitative earnings or revenue guidance. Management describes expected demand growth for the manufacturing segment and discusses potential peak U.S. sales estimates for AVERSA Fentanyl ($80–200 million) and AVERSA Buprenorphine ($70–130 million), based on third-party market assessments; these are estimates for products still under development, not company guidance or realized sales.
Most important facts for investors to verify
- Current cash, runway, burn rate, and the terms and remaining availability of the related-party credit line after the April 2024 financing.
- Use of proceeds from the $8.4 million financing, fully diluted share count, and potential warrant exercises and dilution.
- Kindeva deliverables, spending against the estimated $8.1 million remaining cost, clinical-study timing, and the basis for the stated 12–18-month FDA submission expectation.
- Whether the FDA accepts the proposed 505(b)(2) pathway and the planned scope of testing and abuse-deterrent labeling.
- Progress in remediating material weaknesses in internal controls and the basis for management’s going-concern conclusion.
- Developments, potential exposure, and any subsequent resolution of the Gunnar/Lucosky litigation and the Sorrento-related receivable/factoring obligation.